BTIG analyst Julian Harrison downgraded Prometheus (RXDX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) for $200 per share. The deal makes sense as it fills a "large void" in Merck’s pipeline, the analyst tells investors in a research note. Prometheus’ PRA023 remains in the pole positions for ulcerative colitis and Crohn’s disease, says the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Moderna & Merck Are Better Together
- Merck Acquiring Prometheus Biosciences
- Merck acquires Prometheus Biosciences for $200 per share
- Merck’s Keytruda application in adenocarcinoma accepted by FDA
- Merck upgraded to Buy from Neutral at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue